稳心颗粒联合倍他乐克治疗冠心病合并室性早搏的临床观察

目的:观察稳心颗粒联合倍他乐克治疗冠心病合并室性早搏的临床疗效及安全性。方法:将108例冠心病合并室性早搏患者随机分为治疗组和对照组各54例,治疗组给予稳心颗粒联合倍他乐克治疗,对照组仅给予服倍他乐克治疗,比较两组患者的动态心电图结果、临床疗效及不良反应。结果:治疗组的动态心电图结果和临床疗效均优于对照组,且差异有统计学意义(P<0.05)。两组患者的不良反应发生率比较无明显差异(P>0.05)。结论:稳心颗粒联合倍他乐克治疗冠心病合并室性早搏疗效优于单用倍他乐克,且联合用药可减小倍他乐克的使用剂量,不良反应小,患者的耐受性好,值得临床借鉴。

Clinical observation on treating coronary heart disease and premature ventricular contractions by Wenxin granule plus betaloc

Objective： To observe the clinical efficacy and safety of Wenxin granule plus betaloc. Methods： 108 cases were randomly divided into the treated group and the control group, 54 cases for each group;the treated group was given Wenxin granule plus betaloc, the control group taking the betaloc treatment, ambulatory ECG results, clinical efficacy and adverse reactions in two groups were compared. Results： Ambulatory ECG results and clinical efficacy in the treated group was better, and the difference was statistically significant （P〈0.05）. There was no significant difference （P〉0.05） in incidence of adverse reactions of the two groups of patients. Conclusion：The efficacy of Wenxin granule plus betaloc was better than betaloc only, combination therapy may reduce the dose of betaloc, less adverse reaction, well the tolerance of patients, worthy of reference.